Vifor Pharma AG (OTCMKTS:GNHAF) has earned an average rating of “Hold” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the company.
GNHAF has been the subject of several recent analyst reports. Barclays restated an “equal weight” rating on shares of Vifor Pharma in a research note on Wednesday, February 10th. UBS Group upgraded Vifor Pharma from a “sell” rating to a “neutral” rating in a research note on Monday, March 1st.
Shares of Vifor Pharma stock remained flat at $$144.19 on Thursday. Vifor Pharma has a 12-month low of $125.38 and a 12-month high of $149.99. The business has a 50 day moving average price of $140.91.
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).
Read More: Stock Market – What is a circuit breaker?
Receive News & Ratings for Vifor Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vifor Pharma and related companies with MarketBeat.com's FREE daily email newsletter.